AstraZeneca (LON:AZN) Given Hold Rating at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Tuesday, Digital Look reports. They currently have a £117 target price on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential downside of 5.86% from the company’s current price.

Other analysts also recently issued research reports about the stock. Royal Bank Of Canada reissued an “outperform” rating and issued a £145 price objective on shares of AstraZeneca in a research note on Tuesday, September 8th. Berenberg Bank cut their target price on AstraZeneca from £160 to £150 and set a “buy” rating on the stock in a research note on Tuesday, September 15th. Citigroup increased their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Finally, Jefferies Financial Group reissued a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Wednesday, September 9th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of £150.

AstraZeneca Trading Down 0.5%

Shares of AstraZeneca stock traded down GBX 64 during trading on Tuesday, hitting £124.28. The stock had a trading volume of 263,798,469 shares, compared to its average volume of 31,665,602. AstraZeneca has a 12 month low of £109.22 and a 12 month high of £157.32. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. The firm’s fifty day simple moving average is £121.73 and its 200-day simple moving average is £133.31. The stock has a market cap of £192.75 billion, a PE ratio of 18.60, a PEG ratio of 0.86 and a beta of 0.20.

Insiders Place Their Bets

In related news, insider Michel Demare acquired 2,500 shares of the stock in a transaction on Monday, September 14th. The stock was bought at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is owned by insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.